Maastricht University

Molecular biology and pathophysiology of APC resistance

Citation for published version (APA):

Document status and date:
Published: 01/01/1998

DOI:
10.1055/s-2007-996021

Document Version:
Publisher's PDF, also known as Version of record

Please check the document version of this publication:

• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

Download date: 03 Jun. 2020

Molecular Biology and Pathophysiology of APC Resistance: Current Insights and Clinical Implications

JAN ROSING, Ph.D, H. COENRAAD HEMKER, Ph.D., and GUIDO TANS, Ph.D.

ABSTRACT APC resistance is often associated with the occurrence of a single point mutation in factor V (factor V_{Leiden}) at a predominant cleavage site for the natural anticoagulant, activated protein C (APC). In this article we will discuss the effects of this mutation ($Arg^{506} \rightarrow Gln$) on the down-regulation of factor Va cofactor activity and on thrombin formation by APC in model systems and in plasma. Our studies on the effects of APC on thrombin formation in plasma resulted in the development of a new method for the screening of APC resistance that is based on measurement of the effect of APC on the endogenous thrombin potential (the time integral of thrombin generated in clotting plasma). It appeared that sensitivities for APC determined via this method were considerably affected by the use of oral contraceptives (OC) and that women who use OC become acquired APC resistant. The fact that acquired APC resistance in women who use third-generation OC was more pronounced than in users of second-generation OC may explain the further increased risk for venous thrombosis associated with the use of third-generation OC.

Keywords: APC resistance, factor V_{Leiden}, oral contraceptives, venous thrombosis

Some 20 years ago it was recognized that the activated form of the plasma protein protein C, called APC, is a serine protease that down-regulates thrombin forma-

Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands

Reprint requests: Dr. Rosing, Department Biochemistry, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.

tion via limited proteolysis of factor Va.[1,2] Soon afterwards, it was reported that efficient inactivation of factor Va by APC required the presence of negatively charged phospholipids[3–6] and another vitamin K-dependent plasma protein, protein S.[4,5,7,8]

The protein C pathway presently attracts much attention of clinical and research laboratories. This is due to the fact that in 1993 Björn Dahlbäck[9] discovered a new risk factor for familial venous thrombosis that is characterized by inherited resistance to APC. About 1 year later it was reported[10–13] that APC resistance is caused by a single point mutation in the factor V gene that results in the replacement of an amino acid at a predominant cleavage site for APC.

In this article we will discuss the effects of this mutation on APC-catalyzed factor Va activation in model systems and on the down-regulation of thrombin formation by APC in plasma. These studies have led to the development of new methods for the screening of hereditary and acquired APC resistance.

INACTIVATION OF FACTOR Va AND FACTOR Va_LEIDEN IN MODEL SYSTEMS

Factor Va, the protein cofactor of the prothrombin-activating complex, is a heterodimer that consists of a heavy and a light chain held together by a single calcium ion. In 1994 the group of Mann[14] reported that APC can cleave three peptide bonds in the heavy chain of human factor Va, which are located at positions Arg^{306}, Arg^{506}, and Arg^{679} (Fig. 1). Sequence analysis of the factor V gene has shown that in APC-resistant individuals the arginine at position 506 is replaced by glutamine.[10–13] To get more insight into the consequences of this mutation, several laboratories[15–19] have purified factor Va from homozygous APC-resistant individuals (factor V_{Leiden}) and compared its sensitivity for APC with that of normal fac-

FIG. 1. APC cleavage sites in human factor Va. In factor Va$_{Leiden}$, Arg^{506} is replaced by Gln.

tor Va in model systems containing purified proteins and artificial phospholipid vesicles.

Figure 2 shows that normal factor Va is inactivated by APC via a biphasic reaction that consists of a rapid phase that yields a reaction intermediate that retains approximately 40% of the cofactor activity of native Va and that is subsequently fully inactivated via a second, slow reaction.[17] Factor Va$_{Leiden}$ is inactivated via a slow monophasic reaction, the initial rate of which is some 20-fold lower than that of normal Va. Detailed kinetic analysis showed that inactivation of factor Va$_{Leiden}$ proceeds at a rate that is approximately similar to that of the second phase of normal factor Va inactivation.[17]

Gel electrophoretic analysis of time courses of inactivation of factor Va and factor Va$_{Leiden}$[17] indicated that the rapid phase of inactivation of normal factor Va is associated with cleavage at Arg^{506} and that inactivation is completed via cleavage at Arg^{306}. Factor Va$_{Leiden}$ is slowly but fully inactivated via a single peptide bond cleavage at Arg^{306}.


FIG. 2. Inactivation of factor Va and factor Va$_{Leiden}$ by APC. Time courses of inactivation of 0.3 nM factor Va (▲) and 0.3 nM factor Va$_{Leiden}$ (■) by 1.5 nM APC were determined in the presence of 25 μM dioleoylphosphatidylserine/dioleoyl phosphatidylcholine (10/90, M/M) vesicles in 25 mM Hepes (pH 7.5), 175 mM NaCl, and 3 mM CaCl$_2$. Data from Nicolaes et al[17] (reprinted with permission).

It is interesting to note that the heavy chain fragments formed after cleavage at Arg^{506} remain associated and that factor Va cleaved at Arg^{506} is still active as a cofactor in prothrombin activation.[17] This reaction intermediate has considerably less affinity for factor Xa and requires approximately 50 times more factor Xa for the expression of cofactor activity in prothrombin activation than native factor Va. As a consequence, factor Va cleaved at Arg^{506} can express variable residual cofactor activity in prothrombin activation depending upon the amount of factor Xa present.

Based on these observations we proposed[17] that normal factor Va can be inactivated by APC via two pathways (Fig. 3), the predominant one being pathway 1, which involves rapid cleavage at Arg^{506} and formation of a factor Va intermediate that still has cofactor activity in prothrombin activation, which is subsequently fully inactivated by slow cleavage at Arg^{306}. The latter peptide bond can be cleaved also directly in factor Va. This is a slow reaction that yields a form of factor Va with negligible cofactor activity in prothrombin activation. Due to the mutation at Arg^{506}, pathway 1 cannot occur in factor Va$_{Leiden}$, which as a consequence can only be slowly inactivated via pathway 2.

It should be emphasized that this is a model for factor Va inactivation by APC alone. However, it has been known for many years that the activity of the protein C pathway is stimulated by protein S[7,8] and that factor Xa protects factor Va against inactivation by APC.[3,20,21] Kinetic analysis[18] of the effects of factor Xa and protein S on time courses of normal factor Va inactivation suggests that factor Xa specifically inhibits the rapid phase of inactivation that is cleavage at Arg^{506} and that protein S accelerates the second phase of inactivation that is associated with cleavage at Arg^{306}. The fact that factor Xa does not protect factor Va$_{Leiden}$ and that protein S accelerates its inactivation more than 20-fold[18] confirms that the target site of protein S is Arg^{306} and that factor Xa specifically inhibits cleavage at Arg^{506}. This suggests that in the presence of factor Xa and protein S factor Va and factor Va$_{Leiden}$ will be inactivated mainly via pathway 2 (Fig. 3), which diminishes the differences in sensitivity of normal factor Va and factor Va$_{Leiden}$ for APC and may explain why APC resistance is only a mild risk factor for venous thrombosis.

SCREENING FOR THE FACTOR V$_{LEIDEN}$ MUTATION BY MEASURING THE EFFECT OF APC ON THROMBIN GENERATION IN PLASMA

On the basis of the information obtained on the down-regulation of factor Va cofactor activity by APC in model systems, we have developed two new methods for the screening of APC resistance.[22–24] In one of the accompanying papers in this issue Michiels and Hamulyák

Pathway I

Pathway II

FIG. 3. Pathways of factor Va and factor Va$_{Leiden}$ inactivation by APC (reprinted with permission).

esent the clinical application of our prothrombinase-
sed assay. In this article we will discuss the possibility
screen for APC resistance by measuring the effect of
PC on the thrombin potential, a valuable diagnostic pa-
meter introduced by Hemker and co-workers some 10
ars ago.[25,26]

When coagulation in a plasma sample is initiated
th thromboplastin and thrombin formation is quanti-
ed with a thrombin-specific chromogenic substrate,
e obtains the so-called thrombin generation curve
ig. 4). The rising part of this curve probes the activa-
n and in some cases also the inactivation of the coagu-
ion factors that are involved in prothrombin activa-
n. The descending part of the curve mainly reflects the
hibition of thrombin by plasma protease inhibitors,
rticularly antithrombin and α-2 macroglobulin (α-2M).

FIG. 4. The thrombin generation curve.

Because the α-2M-thrombin (α-2M-IIa) complex is still
active on chromogenic substrates, the curve ends with a
constant, residual level of amidolytic activity. Using the
rate constant of inhibition of thrombin by α-2M, it is
possible to calculate the amount of α-2M-IIa present at
any moment and correct the thrombin generation curve
for the contribution of this complex.[25] After this correc-
tion, one obtains the amount of free thrombin present in
clotting plasma as a function of time. The surface under
this curve is defined as the endogenous thrombin poten-
tial (ETP), which has a value of 382 nM.min ± 52 (SD)
in plasma samples of normal individuals.[26]

It appears that thrombin generation in normal plasma
can be almost completely abolished by APC (Fig. 5A). The
middle panel of this figure (Fig. 5B) shows the effect of the
same APC concentration on thrombin generation in
plasma of a heterozygous carrier of factor V$_{Leiden}$. It is obvi-
ous that thrombin generation is resistant towards APC and
that approximately two to three times more thrombin is
formed than in normal plasma. Thrombin generation in
plasma of a homozygous carrier of factor V$_{Leiden}$ is even
less affected by APC (Fig. 5C). Visual inspection of the
thrombin generation curves indicates that APC decreases
the thrombin potential in this plasma by less than 50%.

To quantitate the effect of APC on thrombin genera-
tion we defined an APC sensitivity ratio (APC-sr) that is
equal to the ratio of thrombin potentials determined in
the presence and absence of APC. Because the final level
of α-2M-IIa appears to be proportional to the ETP,[23,27,28]
values of the APC-sr calculated from the ETP are the
same as those calculated from final levels of α-2M-IIa

FIG. 5. Effect of APC on thrombin generation in plasma. Thrombin generation was initiated in normal plasma (A), in plasma of a heterozygous (B), or homozygous carrier of factor V_{Leiden} (C) with a phospholipid/$CaCl_2$/tissue factor mixture either in the absence ($\blacktriangle$) or presence ($\bullet$) of APC. Thrombin formation was determined with the chromogenic substrate D-Phe-(pipecolyl)-Arg-pNA (S2238). The amidolytic activity was corrected for the contribution of the α-2M-IIa complex. Further details are given in Nicolaes et al[23] (reprinted with permission).

FIG. 6. n-APC-sr of normal individuals, heterozygous and homozygous carriers of factor V_{Leiden} determined by measuring the effect of APC on the endogenous thrombin potential. Data from Nicolaes et al[23] and Rosing et al.[33]

$$nAPC\text{-}sr = (\alpha_2M\text{-}IIa_{+APC}/\alpha_2M\text{-}IIa_{-APC})_{plasma\ sample}/$$
$$(\alpha_2M\text{-}IIa_{+APC}/\alpha_2M\text{-}IIa_{-APC})_{normal\ plasma\ pool}.$$

It should be emphasized that due to the calculation procedure, nAPC-sr determined with the thrombin potential method shows trends that are the reverse of those obtained with assays based on the determination of the effect of APC on the activated partial thromboplastin time (APTT).[29] Thus, with the thrombin potential method, normal plasmas will give nAPC-sr ~1, while APC-resistant plasmas will give higher nAPC-sr than normal plasma.

Figure 6 shows the result of a determination of the nAPC-sr with the thrombin potential method of a large number of plasma samples from healthy individuals and

FIG. 7. Effect of OC therapy on n-APC-sr determined by measuring the effect of APC on the endogenous thrombin potential. The populations are: women who do not use OC (no OC), women who use second-generation monophasic OC (MP2), women who use third-generation monophasic OC (MP3), and heterozygous female carriers of the factor V_{Leiden} mutation who do not use OC (FV_{Leiden}). Data from Rosing et al.[33]

determined after 15–20 min. To increase day-to-day reproducibility, data were expressed as normalized APC-sensitivity ratios (nAPC-sr) by dividing the APC-sr through the same ratio determined in a normal pooled plasma. Hence, the n-APC-sr can be also calculated according the formula:

TABLE 1.   APC Sensitivity Ratios and Risks of Venous Thrombosis of OC Users and Heterozygous and Homozygous Carriers of Factor V$_{Leiden}$

Women		n	nAPC-sr[a] (95–95 percentile)	Risk Increase
No FV$_{Leiden}$	no OC	53	0.87–2.15	—
No FV$_{Leiden}$	MP3	40	1.91–3.88	6–8[b]
Heterozygous FV$_{Leiden}$	no OC	17	2.09–6.60	7[c]
Heterozygous FV$_{Leiden}$	OC	6	4.53–6.45	30–50[d,e]
Homozygous FV$_{Leiden}$	no OC	5	3.91–6.02	>50[f]

Data from [a]Rosing et al,[33] [b]WHO,[36] [c]Koster et al,[42] [d]Vandenbroucke et al,[43] [e]Bloemenkamp et al,[44] and [f]Rosendaal et al.[45]
MP3, users of third generation monophasic OC.

from heterozygous and homozygous carriers of factor V$_{Leiden}$. It appears that the majority of the normal plasma samples indeed had a nAPC-sr around 1 and that carriers of the factor V$_{Leiden}$ mutation had nAPC-sr higher than 2. It was, however, not possible to discriminate fully normal individuals from carriers of factor V$_{Leiden}$ because there was some overlap between the nAPC-sr of these populations.

OC THERAPY AND ACQUIRED APC RESISTANCE

The data presented above indicate that the ETP test is not 100% decisive like DNA analysis,[30] a prothrombinase-based assay,[22,24] or an APTT-based test performed in factor V-deficient plasma[31,32]; and one may question the usefulness of APC-resistance tests that are not 100% specific for the factor V$_{Leiden}$ mutation. We feel, however, that a functional test that is influenced by other plasma components and hence yields a distribution of APC-sr may contain valuable information regarding the prothrombotic status of an individual. This can be illustrated on the basis of an extensive study of plasmas of women using oral contraceptives (OC), which shows that APC-sr determined with the ETP method are strongly influenced by the use of OC and may be a good parameter to investigate the effects of OC on the hemostatic process.[33]

During the development of our assay, we observed that women who used OC had significantly higher APC-sr than women who did not take OC, that is, were less sensitive to APC and hence acquired APC resistant (Fig. 7). It is interesting to note that the APC-sr of plasmas of women who take third-generation monophasic OC containing desogestrel or gestodene were significantly higher than those of women who used second-generation monophasic OC containing levonorgestrel of lynestrenol and did not significantly differ from the APC-sr of heterozygous APC-resistant women who were not using OC.

These observations indicate that OC therapy induces acquired APC resistance, the extent of which depends on the kind of OC used. Acquired APC resistance may well explain the higher risk of thrombotic disease of women taking OC[34] and the different risks reported for women who use second- or third-generation OC.[35–38] This proposal is supported by the fact that there appears to be a good correlation between the values of the nAPC-sr determined with the ETP method and the increased risk for deep-vein thrombosis in women who use third-generation OC and in carriers of factor V$_{Leiden}$ (Table 1). During our study we identified six women who were using OC and who were also heterozygous carriers of the factor V$_{Leiden}$ mutation. These women had APC-sr that are normally observed for individuals that are homozygous for the factor V$_{Leiden}$ mutation and who do not use OC. The fact that the risk increase for venous thrombosis of heterozygous pill users and homozygous nonusers are similar further supports our proposal that the increased incidence of venous thrombosis in congenital APC-resistant individuals and in women using OC may originate from a defect in the same physiological pathway.

Unfortunately, we have as yet no information about the molecular mechanism by which OC induce acquired APC resistance. In this respect we would like to emphasize that also according to the APTT-based assay, the use of OC is associated with acquired APC resistance.[39–41] The effects of OC on APC-sr determined with the APTT-based method are, however, much less pronounced and as yet no significant differences were reported between APC-sr determined with this method in plasma of users of second- and third-generation OC. Because the major difference between the APTT- and ETP-based assays is the fact that in the APTT coagulation is initiated via the intrinsic pathway and in the ETP method is initiated via the extrinsic pathway, this may indicate that the major point of attack of OC likely has to be sought in the activity or regulation of extrinsic coagulation pathway.

REFERENCES

1. Stenflo J. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J Biol Chem 1976;251:355–363

2. Kisiel W, Canfield WM, Ericsson LH, Davie EW. Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry 1977;16:5824–5831

3. Walker FJ, Sexton PW, Esmon CT. The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta 1979;571: 333–342

4. Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane-bound factor Va by activated protein C. J Biol Chem 1988;263:14884–14890

5. Bakker HM, Tans G, Janssen Claessen T, et al. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem 1992;208:171–178

6. Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994;269:816–819

7. Walker FJ. Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem 1980;255: 5521–5524

8. Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981;256:11128–11131

9. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004–1008

10. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64–67

11. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994;343:1361–1362

12. Voorberg J, Roelse JC, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994;343:1535–1536

13. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536–1538

14. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994;269:31869–31880

15. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor V R506Q. J Biol Chem 1995; 270:4053–4057

16. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: Molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995;85:3405–3411

17. Nicolaes GAF, Tans G, Thomassen MCLGD, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor Va R506Q by activated protein C. J Biol Chem 1995;270:21158–21166

18. Rosing J, Hoekema L, Nicolaes GAF, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor Va R506Q by activated protein C. J Biol Chem 1995;270:27852–27858

19. Aparicio C, Dahlbäck B. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. Biochem J 1996;313:467–472

20. Suzuki K, Stenflo J, Dahlbäck B, Teodorsson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1983;258:1914–1920

21. Nesheim ME, Canfield WM, Kisiel W, Mann KG. Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J Biol Chem 1982;257:1443–1447

22. Nicolaes GAF, Thomassen MCLGD, van Oerle R, et al. A prothrombinase-based assay for detection of resistance to activated protein C. Thromb Haemostas 1996;76:404–410

23. Nicolaes GA, Thomassen MC, Tans G, Rosing J, Hemker HC. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coag Fibrinolysis 1997;8:28–38

24. van Oerle R, van Pampus L, Tans G, Rosing J, Hamulyák K. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance. Am J Clin Pathol 1997;107:521–526

25. Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemostas 1986;56:9–17

26. Hemker HC, Béguin S. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. Thromb Haemostas 1995;74:134–138

27. Duchemin J, Pittet JL, Tartary M, et al. A new method based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thromb Haemostas 1994;71: 331–338

28. Hemker HC, Wielders SJH, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for determination of the thrombin potential. Thromb Haemostas 1993; 70:617–624

29. De Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: A critical evaluation of the test and the development of diagnostic criteria. Thromb Haemostas 1994;72:880–886

30. Beauchamp NJ, Daly ME, Cooper PC, Preston FE, Peake IR. Rapid two-stage PCR for detecting factor V G1691A mutation. Lancet 1994;344:694–695

31. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344:1162–1163

32. Trossaert M, Conrad J, Horellou MH, et al. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344:1709

33. Rosing J, Tans G, Nicolaes GAF, et al. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997;97:233–238

34. Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med 1981;305:612–618

35. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational research group on oral contraceptives and the health of young women. Br Med J 1996;312:83–88

36. WHO. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575–1582

37. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components [see comments]. Lancet 1995;346: 1589–1593

38. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Factor V Leiden and third-generation oral contraceptives—Reply. Lancet 1996;347:396–397

39. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995;91:465–470

40. Henkens CMA, Bom VJJ, Seinen AJ, Van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemostas 1995;73:402–404

41. Meinardi JR, Henkens CMA, Heringa MP, Meer van der J. Acquired APC resistance related to oral contraceptives and pregnancy and its possible implications for clinical practice. Blood Coag Fibrinolysis 1997;8:152–154

42. Koster T, Rosendaal FR, De Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503–1506

43. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453–1457

44. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet 1995;346:1593–1596

45. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504–1508